KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accumulated Expenses (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Accumulated Expenses for 16 consecutive years, with $650680.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 67.82% to $650680.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $650680.0 through Dec 2025, down 67.82% year-over-year, with the annual reading at $650680.0 for FY2025, 67.82% down from the prior year.
  • Accumulated Expenses hit $650680.0 in Q4 2025 for Inovio Pharmaceuticals, down from $955970.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $13.6 million in Q3 2021 to a low of $650680.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $6.4 million across 5 years, with a median of $5.6 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: surged 133.15% in 2021 and later tumbled 78.74% in 2025.
  • Year by year, Accumulated Expenses stood at $10.3 million in 2021, then increased by 2.59% to $10.6 million in 2022, then crashed by 77.67% to $2.4 million in 2023, then decreased by 14.52% to $2.0 million in 2024, then plummeted by 67.82% to $650680.0 in 2025.
  • Business Quant data shows Accumulated Expenses for INO at $650680.0 in Q4 2025, $955970.0 in Q3 2025, and $1.5 million in Q2 2025.